- Home
- NBXG vs CTMX Comparison
NBXG vs CTMX Comparison
Compare NBXG & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBXG | CTMX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 977.1M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NBXG | CTMX |
|---|---|---|
| Price | $16.70 | $3.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.10 |
| AVG Volume (30 Days) | 218.1K | ★ 2.9M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.61 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.32 | $1.72 |
| 52 Week High | $16.59 | $8.21 |
Technical Indicators
Market Signals| Indicator | NBXG | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 75.07 | 36.09 |
| Support Level | $14.40 | $3.40 |
| Resistance Level | N/A | $3.91 |
| Average True Range (ATR) | 0.31 | 0.18 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 87.44 | 21.58 |
Price Performance
Historical ComparisonAbout NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.